MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.610
+0.200
+8.30%
After Hours: 2.550 -0.06 -2.30% 16:00 11/26 EST
OPEN
2.380
PREV CLOSE
2.410
HIGH
2.640
LOW
2.353
VOLUME
526.98K
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
2.170
MARKET CAP
37.61M
P/E (TTM)
-1.6939
1D
5D
1M
3M
1Y
5Y
ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week
It might be of some concern to shareholders to see the ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price down 20% in...
Simply Wall St. · 11/20 12:01
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest...
Investor Brand Network · 11/15 19:41
Minerva Advisors LLC Buys FreightCar America Inc, Nicolet Bankshares Inc, Lumos Pharma Inc, ...
GuruFocus News · 11/12 19:38
ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th
WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine...
Globe Newswire · 11/09 21:15
ARCA biopharma reports Q3 results
ARCA biopharma (NASDAQ:ABIO): Q3 GAAP EPS of -$0.33. Cash and cash equivalents of $58.3 million at September 30, 2021, sufficient to fund operations through 2022. Press Release
Seekingalpha · 11/02 20:54
ARCA biopharma Q3 EPS $(0.33), Same YoY
ARCA biopharma (NASDAQ:ABIO) reported quarterly losses of $(0.33) per share. This is unchanged from the same period last year.
Benzinga · 11/02 20:46
BRIEF-Arca Biopharma Reports Q3 Loss Per Share $0.33
reuters.com · 11/02 20:40
ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged
The Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis for ARCA biopharma Inc's (NASDAQ: ABIO) ASPEN-COVID-19 Phase 2b trial evaluating rNAPc2, a small recombinant protein for COVID-19.
Benzinga · 10/29 10:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABIO. Analyze the recent business situations of ARCA BIOPHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
High7.00
Average7.00
Low7.00
Current 2.610
EPS
Actual
Estimate
-1.95-1.46-0.98-0.49
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 29
Institutional Holdings: 1.67M
% Owned: 11.56%
Shares Outstanding: 14.41M
TypeInstitutionsShares
Increased
7
349.53K
New
6
44.12K
Decreased
4
28.34K
Sold Out
4
30.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
Non-Executive Chairman/Independent Director
Robert Conway
Chief Executive Officer/President/Director
Michael Bristow
Chief Financial Officer/Chief Accounting Officer
C. Jeffrey Dekker
Chief Operating Officer
Thomas Keuer
Senior Vice President/General Counsel/Secretary
Christopher Ozeroff
Vice President
Christopher Graybill
Independent Director
Linda Grais
Independent Director
Anders Hove
Independent Director
Daniel Mitchell
Independent Director
Raymond Woosley
No Data
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.